GU Cancer Clinical Trials

DISCLAIMER: All content found on cua.org is provided for information and education purposes. The medical information and clinical trials information is not intended to substitute for the advice of a physician, nor is it intended to provide legal advice. You should always consult your doctor for specific information on personal health matters, or other relevant professionals to ensure that your own circumstances are considered.

The CUA is not responsible in any manner for direct, indirect, special or consequential damages caused and/or arising from your use of cua.org.

Subspecialty
Prostate | QC | Recruiting
PROSTEP-002
Detecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer.
Dr. Frédéric Pouliot
Start Date: March 22, 2022

NCT #: NCT04655365

SPONSOR: CHU de Quebec-Universite Laval in collaboration with Astellas

INFO: https://clinicaltrials.gov/ct2/show/NCT04655365

CONTACT:  418 525-4444 ext 20417

Renal | ON | Recruiting
2021-004968-95
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
GlaxoSmithKline
Start Date: March 22, 2022

NCT #: 2021-004968-95

SPONSOR: GlaxoSmithKline

INFO: https://clinicaltrials.gov/ct2/show/NCT05277051?recrs=abf&cond=Renal+Cell+Carcinoma&cntry=CA&draw=2&rank=31

CONTACT: GSKClinicalSupportHD@gsk.com 

OTHER CANADIAN CENTRES:

Princess Margaret Cancer Centre (Toronto)

 

Prostate | ON | Recruiting
ROADSTER
Radioligand for local radiorecurrent prostate cancer
Dr. Glen Bauman
Start Date: March 17, 2022

NCT #: NCT05230251

SPONSOR: London Health Sciences Foundation

INFO: https://clinicaltrials.gov/ct2/show/NCT05230251

CONTACT:  519-685-8500

Renal | AB, BC, ON, QC | Recruiting
LITESPARK-022
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
Merck Sharp & Dohme LLC
Start Date: March 15, 2022

NCT #: NCT05239728

SPONSOR: Merck Sharp & Dohme LLC

INFO: https://clinicaltrials.gov/study/NCT05239728

CONTACT: 1-888-577-8839                        

Trialsites@merck.com 

Other Canadian Centres:

Centre intégré de cancérologie (Hôpital de l'Enfant-Jésus) (Quebec).                          

Tom Baker Cancer Center (Calgary)                                                                                    

BC Cancer Vancouver Clinical Trials Unit (Vancouver)                                                            

Hamilton Health Sciences (JCC) (Hamilton)                                                                        

Victoria Hospital & Children's Hospital (London)                                                            

Princess Margaret Cancer Centre (Toronto)                                                                          

CIUSSS de l'Est-de-l'Île-de-Montréal (CHUS): Montreal                                                                        

McGill University Health Centre (Montreal)

Prostate | AB | Recruiting
HREBA.CC-21-0073
18F-PSMA PET and MRI in the Primary Staging of Prostate Cancer Patients
Dr. Alexander Tamm & Dr. Adam Kinnaird
Start Date: February 10, 2022

NCT #: NCT05141760

SPONSOR: University of Alberta in collaboration with the Canadian Urological Association Scholarship Foundation.

INFO: https://clinicaltrials.gov/ct2/show/NCT05141760

CONTACT:  780-407-5800 ext 321

Renal | AB | Currently on hold
SMART
Study of Minimally-invasive Ablative Renal Therapies (SMART) Registry (SMART)
Dr. Adam Kinnaird & Dr. Nicholas Dean
Start Date: January 27, 2022

NCT #: NCT05210933

SPONSOR: University of Alberta

INFO: https://clinicaltrials.gov/ct2/show/NCT05210933?recrs=abf&cond=Renal+Cell+Carcinoma&cntry=CA&draw=2&rank=3

CONTACT:

780-951-2326

780-690-6285

OTHER CANADIAN CENTRES: Calgary & Edmonton

Prostate | QC | Recruiting
PCS-XI
Pelvic Nodes Ultra-Hypo vs Conventionally Fractionated IMRT With HDR Boost in Prostate Cancer
Dr. Andre-Guy Martin
Start Date: January 9, 2022

NCT #: NCT05820633

SPONSOR: CHU de Quebec-Universite Laval

INFO: https://clinicaltrials.gov/study/NCT05820633

CONTACT: 

1. Dr. Andre-Guy Martin;  andre-guy.martin.med@ssss.gouv.qc.ca
2. Josee Allard; josee.allard@chudequebec.ca

Other Canadian Centres: CHU du Quebec

Prostate | BC | Recruiting
PROMPT
5500/​20 vs. SABR or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment (PROMPT)
Dr. Juanita Crook
Start Date: December 7, 2021

NCT #: NCT04610372

SPONSOR: British Columbia Cancer Agency

INFO: https://clinicaltrials.gov/study/NCT04610372

CONTACT: 

1. Dr. Juanita Crook (Kelowna) 
Phone:250-712-3958                 
Email: jcrook@bccancer.bc.ca                                                                             
2. Dr. Winkle Kwan (Surrey)                                
Email: wkwan@bccancer.bc.ca                                                 
3. Dr. Mira Keyes (Vancouver)                                          
4. Dr. Saibishkumar Elantholi Parmeswaran (Victoria)    
Email: skumar@bccancer.bc.ca

OTHER CANADIAN CENTRES: 

1. Kelowna, British Columbia (Recruiting)
2. Surrey, British Columbia (Not Yet Recruiting)                                                   
3. Vancouver, British Columbia (Not Yet Recruiting)                                   
4. Victoria, British Columbia (Recruiting)

Renal | AB, QC | Recruiting
SAMETA
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC (SAMETA)
AstraZeneca
Start Date: October 28, 2021

NCT #: NCT05043090

SPONSOR: AstraZeneca

INFO: https://clinicaltrials.gov/ct2/show/NCT05043090?recrs=abf&cond=Renal+Cell+Carcinoma&cntry=CA&draw=2&rank=9

CONTACT:  1-877-240-9479

OTHER CANADIAN CENTRES: Tom Baker Cancer Centre (Calgary), Jewish General Hospital (Montreal)

 

Bladder | AB, ON | Recruiting
MAIN-CAV
Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study
Dr. Shilpa Gupta
Start Date: October 26, 2021

NCT #: NCT05092958

SPONSOR: National Cancer Institute (NCI)

INFO: https://classic.clinicaltrials.gov/ct2/show/NCT05092958

CONTACT: 

Edmonton Contact: 780-432-8500                         

Toronto Contact: clinical.trials.@uhn.on.ca

OTHER CANADIAN CENTRES:

Cross Cancer Institute (Edmonton): Dr. M.P. Kolinsky                                    

University Health Network (Toronto): Dr. Srikala S. Sridhar

The Canadian Urological Association (CUA) does not provide professional medical advice, diagnosis or treatment and cannot respond to requests for direct feedback, specific patient information or physician referrals. You should first always seek the advice of your urologist, physician and other qualified health provider with any questions regarding your medical condition. The contents of the CUA Website such as text, graphics, images, and other content are for informational purposes only. The content/information is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on the CUA website.

For comments or information, email Corporate.office@cua.org

Privacy Policy